Captopril, an angiotensin‐converting enzyme inhibitor with antihypertensive properties, was
given by mouth and intravenously in 10‐mg doses to five healthy subjects. After intravenous …

Angiotensin-converting enzyme (ACE) activity was found to be present within the rat aorta
using radioenzymatic techniques. Forty-two percent of the enzyme activity was localized …

Short‐term hypertensive and hormonal effects of Captopril were studied in 26 hypertensive
patients. Blood pressure (BP) and heart rate were recorded in subjects in the supine position …

Captopril, the first orally active inhibitor of angiotensin-converting enzyme, is used widely in
the treatment of hypertension and congestive heart failure. The pharmacokinetics of this …

The usual regimens of captopril-twice or thrice daily administration-are based on the
duration of the decrease in plasma angiotensin II induced by captopril. In a study performed …

Captopril, an inhibitor of angiotensin converting enzyme, was administered twice daily to 13
hypertensive patients for a mean period of 9 weeks. Continuous blood pressure control in …

In rats treated continuously with captopril (80 μg/h, ip), for 2 days, blood pressure decreased
and adrenal angiotensin II receptor concentration was decreased from 160 fmol/mg protein …

The effects of captopril and of other angiotensin-converting enzyme inhibitors (zofenopril,
fosenopril and enalaprilic acid) were tested on the isolated rabbit heart and aorta. Captopril …

Captopril (Capoten) hasbeen evaluated in the treatment both of hypertension and cardiac
failure (Atkinson & Robertson, 1979). However, it is currently indicated only for severe or …

1. Sixty-two patients (nineteen mild-moderate, forty-three severe hypertension) were treated
with captopril. 2. Blood pressure was controlled long term (with/without diuretics/beta …